Birx Deborah 4

What Happened
Deborah Birx, Chief Executive Officer of Armata Pharmaceuticals, had 4,919 shares withheld by the company to satisfy tax withholding obligations related to the net settlement of restricted stock units. The shares were valued at $10.54 each, for a total disposition of $51,846.

Key Details

• Transaction date: 2026-03-14; Filing date: 2026-03-17 (Form 4 accession 0001104659-26-029711).
• Transaction type/code: F — shares withheld to satisfy tax withholding (reported as disposed).
• Shares involved: 4,919 @ $10.54 = $51,846.
• Footnote: F1 — withholding was to satisfy the company's income tax and remittance obligations in connection with net settlement of restricted stock units.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• No late-filing flag was provided in the excerpt.

Context
This is a routine tax-withholding disposition tied to RSU settlement, not an open-market sale. Such withholdings are common and do not necessarily indicate the insider is reducing their position for investment reasons. Purchases generally carry more weight as a bullish signal than routine tax withholdings.